No group differences in age (F = 2.547; P = 0.124), sex (χ2 = 0.490; P = 0.484), disease duration (F = 1.199; P = 0.284), levodopa equivalents (F = 0.034; P = 0.856), MDS UPDRS-III score (F = 0.732; P = 0.403), Hoehn and Yahr score (F = 0.426; P = 0.521) or MoCA (F = 0.173; P = 0.681) were observed between moderate PD patients with LRRK2 and GBA1 mutations. This evidence concerns the gene LRRK2 and Parkinson disease.